Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2019-10-18 Capital/Financing Update
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée aux banques garantes de son augmentation de capital et de son introduction en bourse sur le nasdaq global select market
Capital/Financing Update Classification · 98% confidence The document is a press release from Innate Pharma dated October 18, 2019, announcing the full exercise of the over-allotment option granted to the underwriters of its capital increase and listing on NASDAQ. Key phrases include 'augmentation de capital' (capital increase), 'introduction en bourse sur le NASDAQ' (listing on NASDAQ), and the finalization of the offering size. This clearly relates to fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). Although it is a press release, its core subject matter is the financing event itself, not just the announcement of a report (which would be RPA or RNS).
2019-10-18 French
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée aux banques garantes de son augmentation de capital et de son introduction en bourse sur le nasdaq global select market
Capital/Financing Update Classification · 98% confidence The document is a press release dated October 18, 2019, announcing that the underwriters have exercised the full over-allotment option related to a capital increase and listing on NASDAQ. The key phrases are 'AUGMENTATION DE CAPITAL ET DE SON INTRODUCTION EN BOURSE' (Capital Increase and IPO) and the subsequent announcement about exercising the over-allotment option ('l'exercice intégral de l'option de surallocation'). This directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full 10-K, an ER (which is usually just results), or an IR (Interim Report).
2019-10-18 French
FWP (PRESS RELEASE)
Regulatory Filings
2019-10-17 English
FWP
Regulatory Filings
2019-10-17 English
Innate Pharma annonce la suspension du cours de ses actions ordinaires sur Euronext Paris
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 17, 2019, announcing the temporary suspension of trading of INNATE PHARMA shares on Euronext Paris. The reason cited for the suspension is the introduction (IPO) of the company on the Nasdaq Global Select Market, specifically to allow for the confirmation of allocations and the start of trading for American Depositary Shares (ADSs). This announcement relates directly to capital structure changes and fundraising activities (the IPO). While it is an announcement, it is not a general regulatory filing (RNS) or a report publication announcement (RPA) in the sense of announcing a financial report. It is a specific announcement concerning a major financing/capital event. Therefore, the most appropriate category is 'Capital/Financing Update' (CAP). The document length is relatively short (4753 chars), but the content is a direct announcement of a financing event, not just a notice that a report is attached.
2019-10-17 French
Innate Pharma annonce la suspension du cours de ses actions ordinaires sur Euronext Paris
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Innate Pharma dated October 17, 2019, announcing the suspension of trading of its ordinary shares on Euronext Paris. The suspension is explicitly linked to the introduction of its American Depositary Shares (ADSs) on the Nasdaq Global Select Market. This announcement concerns a significant corporate action related to capital structure and listing changes, specifically the dual listing process. While it relates to capital markets, it is not a formal filing like a 10-K or an ER. It is an announcement regarding a corporate event that impacts its listing status and capital structure. The closest fit among the provided codes is 'Capital/Financing Update' (CAP) as it directly relates to the listing mechanism (a form of financing/capital market activity) and the subsequent trading suspension. However, given the nature of the announcement (suspension of trading due to a listing event), it is a specific corporate action announcement. Since there isn't a specific code for 'Listing Announcement' or 'Trading Suspension', and it is a material corporate event announcement, it falls under the general category of significant corporate news. Given the context of the Nasdaq listing, 'CAP' (Capital/Financing Update) is the most appropriate fit among the specific options, as the Nasdaq listing is a major capital market event. If 'CAP' is too broad, 'RNS' (Regulatory Filings/Miscellaneous) is the fallback, but the event is clearly capital-market related. I will classify it as CAP due to the direct link to the Nasdaq listing introduction.
2019-10-17 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.